Tags

Type your tag names separated by a space and hit enter

[Vitamin D and kidney diseases].
Presse Med. 2013 Oct; 42(10):1391-7.PM

Abstract

Calcitriol and analogs inhibit renin-angiotensin system, which has a pivotal role in glomerular and tubulo-interstitial damages and proteinuria, and inhibit NF-κB activation which is known to play an important role in renal diseases by promoting inflammation and fibrogenesis. Vitamin D presents interesting pleiotropic effects for the CKD patient (reduction of mortality, antiproteinuric effect and anti-inflammatory properties). "Native" vitamin D (cholecalciferol or ergocalciferol) administration in these patients also decrease parathyroid hormone levels. Native vitamin D administration in CKD patients is safe and does not lead to increased risk of vascular calcification, despite the known hypercalcemic and hyperphosphoremic properties of the molecule in its active form. Native vitamin D administration is not associated with an increased risk of renal stones, at pharmacological doses and without important concomitant administration of calcium salts. In the field of renal transplantation, experimental studies show that vitamin D analogs have a protective role against acute rejection but clinical studies remain mainly observational.

Authors+Show Affiliations

CHU de Liège, service de chimie médicale, Liège, Belgique. Electronic address: Etienne.cavalier@chu.ulg.ac.be.No affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

fre

PubMed ID

24055557

Citation

Cavalier, Étienne, et al. "[Vitamin D and Kidney Diseases]." Presse Medicale (Paris, France : 1983), vol. 42, no. 10, 2013, pp. 1391-7.
Cavalier É, Thervet É, Courbebaisse M. [Vitamin D and kidney diseases]. Presse Med. 2013;42(10):1391-7.
Cavalier, É., Thervet, É., & Courbebaisse, M. (2013). [Vitamin D and kidney diseases]. Presse Medicale (Paris, France : 1983), 42(10), 1391-7. https://doi.org/10.1016/j.lpm.2013.07.011
Cavalier É, Thervet É, Courbebaisse M. [Vitamin D and Kidney Diseases]. Presse Med. 2013;42(10):1391-7. PubMed PMID: 24055557.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Vitamin D and kidney diseases]. AU - Cavalier,Étienne, AU - Thervet,Éric, AU - Courbebaisse,Marie, Y1 - 2013/09/20/ PY - 2013/07/01/received PY - 2013/07/10/revised PY - 2013/07/15/accepted PY - 2013/9/24/entrez PY - 2013/9/24/pubmed PY - 2013/12/24/medline SP - 1391 EP - 7 JF - Presse medicale (Paris, France : 1983) JO - Presse Med VL - 42 IS - 10 N2 - Calcitriol and analogs inhibit renin-angiotensin system, which has a pivotal role in glomerular and tubulo-interstitial damages and proteinuria, and inhibit NF-κB activation which is known to play an important role in renal diseases by promoting inflammation and fibrogenesis. Vitamin D presents interesting pleiotropic effects for the CKD patient (reduction of mortality, antiproteinuric effect and anti-inflammatory properties). "Native" vitamin D (cholecalciferol or ergocalciferol) administration in these patients also decrease parathyroid hormone levels. Native vitamin D administration in CKD patients is safe and does not lead to increased risk of vascular calcification, despite the known hypercalcemic and hyperphosphoremic properties of the molecule in its active form. Native vitamin D administration is not associated with an increased risk of renal stones, at pharmacological doses and without important concomitant administration of calcium salts. In the field of renal transplantation, experimental studies show that vitamin D analogs have a protective role against acute rejection but clinical studies remain mainly observational. SN - 2213-0276 UR - https://www.unboundmedicine.com/medline/citation/24055557/[Vitamin_D_and_kidney_diseases]_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0755-4982(13)00678-7 DB - PRIME DP - Unbound Medicine ER -